Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF -2-
March 19, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
March 19, 2001
- Number of Elderly Outpatients Decreases Since January: Hodanren Survey
March 19, 2001
- WORLD NEWS IN BRIEF -1-
March 19, 2001
- Kyoritsu College of Pharmacy to Open Pharmacy
March 19, 2001
- WORLD NEWS IN BRIEF -2-
March 19, 2001
- Measures Taken to Prevent Medical Errors Reported: Safety Seminar
March 19, 2001
- Adsorption Type Hemocatharsis Device Designated as Orphan Device
March 19, 2001
- Novartis to Strengthen Presence in Ophthalmic Field
March 19, 2001
- Teijin: New Blood Glucose Self-Monitoring System
March 19, 2001
- BUSINESS NEWS IN BRIEF -1-
March 19, 2001
- Precious Metals for Dental Use to Be Repriced from April 1
March 19, 2001
- Korosho Issues Brochure on Healthcare Reform to Stimulate Discussions
March 19, 2001
- BUSINESS NEWS IN BRIEF -2-
March 19, 2001
- Fujirebio Aims at No.1 Reagents Maker in 2005
March 19, 2001
- Iwaki, Ohki, Mogi to Operate Joint Distribution System for Retailers
March 19, 2001
- Daiichi Expects to Have Pharmacogenomics Products on the Market in 2012
March 19, 2001
- Chiron, Gen-Probe File Application for HIV-1/HCV Assay
March 19, 2001
- 8 Active Ingredients, Including Herceptin, Zyvox, Recommended for Approval
March 19, 2001
- CQHC to Prepare Standard Format for Ads of Hospital Evaluation Results
March 19, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…